At a glance
ClinicalIndex Comparison RecordN/ACompleted· 290 enrolled
Drug / intervention
Aromatase Inhibitors +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer in Real World Clinical Settings in Greece
In Brief
An observational study evaluating Aromatase Inhibitors and Chemotherapy for Breast Cancer and Other Disorders of Bone Density and Structure. Completed, enrolled 290 participants across 1 site.
Detailed Summary
The purpose of this study is to identify the combined impact on bone loss as well as the incidence of bone fractures in women with estrogen receptor (ER)-positive, early breast cancer treated with an aromatase inhibitor (AI) either as first line therapy or as maintenance therapy after initial treatment with chemotherapy, in real life clinical settings in Greece.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesGreece
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2011
Enrollment StartMar 2011
Primary CompletionDec 2013
Study CompletionMar 2014
TodayJul 2026
First PostedFeb 17, 2011
Enrollment StartMar 1, 2011
Primary CompletionDec 1, 2013
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 15.4 years ago
Interventions
Aromatase Inhibitorsdrug
Chemotherapydrug